BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical
Go back to BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 59.12 -0.85 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.97 | 52 Week High | $108.96 | |||
| Open | $60.15 | 52 Week Low | $62.12 | |||
| Day High | $60.28 | P/E | N/A | |||
| Day Low | $58.44 | EPS | $-1.27 | |||
| Volume | 1,536,630 | |||||
